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Abstract 
Purpose There is controversy about the effect of the rs1799983 Nitric Oxide Synthase (NOS3) 
genetic variant on hypertension and Blood Pressure (BP) levels. The aims of the current study 
were to examine whether rs1799983 affects BP levels and to identify potential interactions 
between this polymorphism and other non-genetic risk factors.  
Methods A total of 705 subjects were examined for anthropometric and body composition 
measurements, BP, dietary habits and physical activity. Oral epithelial cells were collected for 
the identification of rs1799983 using Luminex® 100/200TM System.  
Results After adjusted for covariates, TT genotype showed a 2.30 fold higher predisposition 
of hypertension than GG genotype subjects. According to BP levels, for each risk allele 
diastolic blood pressure (DBP) increased in 1.99 mmHg. Significant interactions between 
rs1799983 and Saturated Fatty Acids (SFA) and Monounsaturated Fatty Acids (MUFA) were 
found. Moreover, an interaction with body weight status was observed. Among overweight 
individuals, T allele carriers showed higher DBP than GG genotype. 
Conclusion The present study evidenced that rs1799983 NOS3 polymorphism could be 
associated with hypertension and DBP among Southern Europeans, being this association 
influenced by dietary fat (SFA and MUFA) and Body Mass Index (BMI). 
 
Keywords 
Hypertension; blood pressure; NOS3; saturated fatty acids; monounsaturated fatty acids; 
obesity
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Introduction 
Hypertension contributes to the burden of heart disease, stroke, kidney failure and premature 
mortality [1]. In fact, hypertension complications account for 9.4 million deaths worldwide 
every year [2]. Key risk factors include age, race, endocrine and metabolic disorders, lifestyle 
behaviors and genetics, among others [1]. 
 
In this context, familial and twin studies have estimated the heritable component of Blood 
Pressure (BP) to be about 30%-60% [3]. Moreover, Genome Wide Association Studies 
(GWAS) have identified a large number of polymorphisms associated with BP or 
hypertension, which are located in or near genes involved in the renin-angiotensin-aldosterone 
system, related to enzymes and receptors of the mineral-and glucocorticoid pathways and 
associated with proteins implicated in the structure and/or regulation of vascular tone [4]. 
 
Among them, the Nitric Oxide Synthase (NOS3) gene is regarded as one of the putative 
candidate gene for BP regulation and hypertension, since it is involved in the production of 
Nitric Oxide (NO) which has vasodilator effects (i.e. inhibiting vascular smooth muscle 
contraction) [5]. Indeed, it has been observed in an animal model that the disruption of NOS3 
gene led to hypertension, while in humans the inhibition of NOS3 elevated BP [5, 6]. 
Between NOS3 genetic variants, the rs1799983 is the most recognized polymorphism related 
not only to BP and hypertension, but also to coronary artery and vascular diseases, myocardial 
infarction, metabolic syndrome and type 2 diabetes [7]. Unfortunately, the results of studies 
seeking associations of rs1799983 and BP or hypertension have not always been consistent in 
different populations, which might be due to gene-environmental risk factors interactions [8]. 
However, to our knowledge, there are few reports on the modulation of environmental factors 
such as excess body weight or diet, two risk factors widely associated with increased BP 
levels and hypertension, on the association between rs1799983 and BP or hypertension [9, 
10]. 
 
Therefore, the aims of the present research were to examine the potential association between 
the rs1799983 NOS3 genetic variant and BP levels and hypertension, and to investigate the 
possible influence of non-genetic risk factors on that association. 
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Study population 
The present study encompassed men and women of Caucasian ancestry who voluntarily 
attended community pharmacies located in 7 regions of Spain (Barcelona, Zaragoza, La 
Coruña, Pontevedra, Madrid, Granada and Málaga). Genotype information of 718 individuals 
was available. Of these 13 subjects were excluded with missing values for dietary intake, 
physical activity, anthropometric measurements and/or blood pressure levels. Therefore, the 
screened group included 705 individuals with a mean age of 50.2±13.2 y.o. Of the total 
population 22.3% (n 157) were male and 77.7% (n 548) were female. 
 
The recruited subjects were specifically asked if they would be willing to take part 
anonymously in the research study. Only those who gave written informed consent for 
participation were enrolled. All procedures were in accordance with the guidelines laid down 
in the Declaration of Helsinki. Patient data were codified to guarantee anonymity. The 
Research Ethics Committee of the University of Navarra provided confirmation of fulfillment 
of the ethical standards affecting this research (ref. 2410/2014). 
 
Anthropometric measurements, habitual dietary intake and physical activity were collected by 
trained nutritionists as described elsewhere [11]. Briefly, weight, height, waist circumference 
and body fat mass were measured with a digital scale (Tanita BF-522W, Tanita Corporation, 
Tokyo, Japan), a portable stadiometer (Leicester Tanita), inextensible tape measure and 
bioelectrical impedance (Tanita BF-522W), respectively. Dietary intake was determined using 
a food frequency questionnaire in which basic foods were classified into 19 food groups, 
where 4 responses were possible (daily, weekly, monthly or never). Physical activity was 
collected by a short 24h physical activity questionnaire [12]. 
 
Blood pressure 
BP was measured using the following standardized protocol with a validated automatic device 
(MIT Elite Plus, OMRON Healthcare, Hoofddorp, Netherland) and appropriately sized cuff 
[13]. Measurements were carried out in the non-dominant arm, with the elbow at the level of 
the right atrium and with the subject in a sitting position. Systolic BP (SBP) and Diastolic BP 
(DBP) were taken two times, separate of at least 10 minutes. The last measurement was used 
in the analysis, discarding the first one. If in the second reading the SBP or DBP were ≥140 
mmHg or ≥90 mmHg, respectively, was performed a third measurement. 
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BP was considered as a categorized variable (hypertension vs normotension) and as a 
continuous variable. In order to dichotomize variables, individuals with a SBP ≥140 mmHg or 
DBP ≥90 mmHg or with declared diagnostic hypertension were defined as “hypertensive”. On 
the other hand, as a continuous variable, BP was treated after adjustment of the BP treatment. 
In this sense, according to previous studies and based on the known average treatment effects, 
fixed increment of 15 mmHg SBP and 10 DBP were added to the pressures of individuals 
with diagnostic hypertension [14-17]. 
 
DNA isolation and genotyping 
Genomic DNA was isolated from oral epithelial cells (collected by ORAcollect DNA®, 
DNAGenotek, Kanata, Canada) by QIAcube using QiAmp DNA Mini QIAcube Kit (Qiagen, 
Hilden, Germany), following the manufacturer’s standard protocol. rs1799983 NOS3 genetic 
variant was genotyped by Luminex® 100/200TM System (Luminex Corporation, Austin, 
Texas), which is based on the principles of xMAP® Technology. This method uncompressed 
polystyrene microspheres internally dyed with various ratios of spectrally distinct 
fluorochromes, that are detected by a flow cytometry-based instrument [18]. 
 
Statistical analysis 
Examination of Hardy Weinberg Equilibrium (HWE) was assessed using the χ2 test and allele 
frequencies were estimated. Quantitative variables are expressed as means (SD), and 
differences among genotype groups were analyzed using general linear models of analysis of 
covariance (ANCOVA) with age, gender, energy intake and physical activity as covariates. 
Multiple logistic regression (categorical variable) and multiple linear regression models 
(continuous variables), adjusted for covariates (model A adjusted for non-modifiable factors 
and model B adjusted for model A plus modifiable factors), were applied to investigate the 
association of the NOS3 polymorphism with hypertension and SBP/DBP, respectively. 
Interactions between rs1799983 (as a dummy variable) and weight status or dietary fatty acid 
intake on BP were investigated using likelihood ratio test, once adjusted for potential 
confounders including gender, age, physical activity, energy intake, smoking status and 
alcohol consumption. All statistical procedures were performed using STATA/SE version 
12.0 (StataCorp, College Station, Tex., USA). Tests were considered statistically significant 
at p value <0.05. 
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Minor allele frequency (MAF) (T=36.9) and genotypic frequencies (GG=40.1, GT=46.0, 
TT=13.9) for rs1799983 were in accordance with the reference data for Caucasian 
populations (HapMap CEU). Moreover, the distribution of the polymorphism was in Hardy 
Weinberg Equilibrium (HWE) (p>0.05). Baseline characteristics of the population have been 
described according to rs1799983 NOS3 genotype subgroups (Table 1). There were no 
statistically significant differences based on genotype for anthropometrical, physical activity 
and dietary variables. Of the 705 individuals, 22.3% (n 157) self-declared hypertension. 
Moreover, about 30.6 % of the individuals self-declared that they suffered one or more 
metabolic disorders: 3.3 % type 2 diabetes, 28.6 % different lipid metabolism impairments 
and 3.1 % cardiovascular disease. 
 
Logistic regression models to estimate odds ratios of self-declared hypertension for 
individuals with the rs1799983 polymorphism were analyzed (Fig. 1). Once adjusted for 
covariates, those subjects with the TT genotype showed a statistically significant 2.30 fold 
higher predisposition of hypertension (95%CI 1.18-4.44; p 0.014) than those subjects with the 
GG genotype. However, individuals with the GT genotype did not show a higher risk of 
hypertension than those with the GG genotype (95%CI 0.82-2.09; p 0.266). Additive and 
recessive model showed a statistically significant 1.46 (95%CI 1.06-2.01; p 0.019) fold per 
risk allele and 1.98 (95%CI 1.08-3.63; p 0.028) fold higher predisposition of hypertension, 
respectively. There were no a higher risk of hypertension when the dominant model was 
applied (OR 1.48 95% CI 0.95-2.30; p 0.084). When the hypertension was defined according 
to blood pressure measurements of the study, once adjusted for hypertensive treatment, no 
statistically significant differences were observed. 
 
Results from linear regression analyses showed an association between rs1799983 and DBP. 
Nevertheless, no relationship with SBP was found (Table 2). Carriers of the T allele had 
significantly greater values of DBP and DBP corrected according to treated hypertensive 
subjects after adjusted for non-modifiable risk factors of hypertension and both non-
modifiable and modifiable risk factors of hypertension. Specifically each additional risk allele 
was associated with a 1.99 mmHg increase in DBP, when DBP was adjusted according to 
treated hypertensive subjects and after statistical analysis was adjusted for gender, age, 
smoking status, alcohol consumption and physical activity. Moreover, GT and TT individuals 
showed a 2.55 mmHg higher DBP than GG individuals after adjusted for non-modifiable and 
6 
 
modifiable covariates. Upon stratifying data by gender, similar results were found among men 
(data not shown). 
185 
186 
187 
188 
189 
190 
191 
192 
193 
194 
195 
196 
197 
198 
199 
200 
201 
202 
203 
204 
205 
206 
207 
208 
209 
210 
211 
212 
213 
214 
215 
216 
217 
218 
 
After data were adjusted for potential confounder variables, Saturated Fatty Acids (SFA) and 
Monounsaturated Fatty Acids (MUFA) modified the effect of the rs1799983 NOS3 genetic 
variant on DBP (Fig. 2). The influence of Body Mass Index (BMI) on the association between 
rs1799983 and DBP was also analyzed (Fig. 3). When the analysis was carried out according 
to the three genotype groups no significant interactions were found. In contrast, when GT and 
TT genotype were clustered, a significant interaction was found. Among normal weight 
individuals no significant differences were found in DBP between GG genotype subjects and 
GT and TT genotype subjects. However, among overweight individuals GT and TT genotype 
subjects showed higher DBP than TT genotype subjects. 
 
 
Discussion 
The current study provides evidence that rs1799983 NOS3 genetic variant is associated with 
an increased odds of hypertension and a high to normal DBP in Southern Europeans. 
Interestingly, an interaction between BMI and dietary fat intake (SFA and MUFA), with the 
rs1799983 polymorphism to influence DBP levels was observed. 
 
In the last few years, increased attention was paid to this NOS3 polymorphism since it is 
directly involved in BP regulation through NO levels [5]. A meta-analysis involving 45,287 
subjects identified that the T allele of the rs1799983 polymorphism was associated with 
hypertension predisposition with an odds ratio of 1.20 (p 0.015) [8]. However, when the 
population was stratified for ethnicity, no significance was reached for Whites (OR 0.99, p 
0.828). It should be highlighted that most of the studies in European population, included in 
the meta-analysis, were carried out in North and Central Europe. In line of our results, a study 
in American white women revealed a hazard ratio of hypertension for rs1799983 NOS3 
genetic variant of 1.05 (p 0.03) [19]. Afterwards reports linked the rs1799983 not only to 
hypertension, but also to left ventricular hypertrophy, coronary artery disease and venous 
thromboembolism, among others [20-22]. In the rs1799983 polymorphism a guanine/thymine 
substitution at exon 7 leads to a glutamate/aspartate substitution at position 298. Since this 
genetic variant alters the primary structure of the protein and could alter one or more 
functional properties of the enzyme, several mechanistic studies have been carried out [23-
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27]. Different reports have revealed that in the presence of a T instead of a G at nucleotide 
position 894, NOS3 encodes a protein which leads to a higher susceptibility to cleavage into a 
100k-Da fragment [23, 24]. Thus, the cleaved fragment could decrease NOS3 activity. 
However, other studies concluded that this finding might be a technical artifact [25, 26]. On 
the other hand, it has been confirmed that T allele carriers have less NOS3 bound to caveolin-
1, which is a protein essential for its activation and therefore to endothelial cell NO 
production [27]. 
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To our knowledge, two previous studies have suggested an influence of rs1799983 NOS3 
genetic variant on DBP [28, 29]. The research by Kimura et al., in African-derived Brazilian 
population, revealed a single two locus effect between rs1799983 and rs1801058, NOS3 and 
GKR4 variants, respectively, on DBP [28]. Lately, Nunes et al. showed that GG genotype 
subjects presented lower exercise DBP than T allele carriers, among Brazilian women [29]. 
Nevertheless, Seidlerová et al. failed to confirm in Europeans the relationship between 
rs1799983 and any arterial properties [30]. It should be mentioned that Delgado-Lista et al. 
reported that after a meal rich in SFA the microvascular endothelial function, which is a 
subclinical condition found in most patients with hypertension, was lower among TG and GG 
genotype subjects than TT genotype subjects of a Spanish population [31]. In one hand, this 
finding suggests a possible ethnic influence on genetic modulation of BP levels responses. On 
the other hand, as other authors have previously suggested gene-environmental interactions 
should be analyzed [8]. 
 
In addition to high sodium intake the scientific literature has established a link between 
dietary fat and increased risk of hypertension [9]. In this sense, we found gene-diet 
interactions between rs1799983 NOS3 genetic variant and SFA and MUFA intakes and the 
effect on DBP. This outcome diverges from the results of Kingah et al. that did not find any 
interaction between the NOS3 genetic variant and dietary fat (total fat, SFA, MUFA and 
polyunsaturated fatty acids -PUFA-) [32]. Nevertheless, our observations are consistent with 
the results of Pereira et al. that suggested a possible gene-diet interaction between rs1799983 
and a diet rich in SFA and cholesterol to influence BP levels [33]. However, the mechanisms 
by which dietary fat modulates the effect of NOS3 genetic variant on BP levels are unknown 
and can at best only be speculated. In line of our results it has been reported in a molecular 
model that a diet rich in olive oil (high MUFA diet) increased the expression of the NOS3 
enzyme. In contrast, a diet rich in SFA decreased the expression of NOS3 [34]. Thus, we 
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hypothesized that carriers of the T allele presented lower effect to dietary fat due to a reduced 
function of NOS3. To establish the mechanism by which dietary fat intake influences BP 
depending on the NOS3 genotype, more studies are needed. 
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Interestingly this study has found a novel interaction between BMI and rs1799983 on the 
modulation of DBP levels. This observation is consistent with the results of Abdel-Aziz et al., 
who described that the association of obesity with TT genotype of rs1799983 polymorphism 
increased the risk to develop premature coronary artery disease in Egyptians [11]. Moreover, 
previous studies have identified the influence of obesity on the relationship between different 
polymorphisms and BP levels or hypertension among adults and children [35-37]. Initial 
epidemiological studies suggesting a relationship between obesity and BP levels have been 
supported with the understanding of potential mechanisms involved in both conditions, such 
as vascular and systemic insulin resistance, dysfuntion of the sympathetic nervous system and 
the renin-angiotensin-aldosterone system, among other pathogenetic factors [10, 38]. On the 
other hand, NOS3 protein content was shown to be significantly lower in overweight and 
obese people and inversely associated with body fat mass [39, 40]. Moreover, oxidative 
stress, a well-known process implicated in obesity, has been related to NOS3 response. In this 
regard, a previous study in an animal model suggested that a reduced NO production and an 
increased production of Reactive Oxygen Species (ROS) may contribute to hypertension in 
obese rats [41]. Therefore, such scientific evidence suggests that our result may be a genuine 
interaction rather than a random chance finding. 
 
The present study bears some strengths and limitations that need to be mentioned. First, this 
study included only subjects of Caucasian ancestry, so our findings may not be generalizable 
to other ethnic populations. Second, the study site could be considered as a random effect. 
However, when the statistical analysis was carried out adjusted for the covariate region the 
analysis gave similar results (data not shown). Third, due to the relatively small sample size 
and the use of a nominal significance threshold p value less than 0.05, the findings may need 
to be replicated in other population. Nevertheless, it was large enough to provide us adequate 
statistical power and the associations and interactions have reached statistical significance in 
this context of limited sample size. Fourth, we did not exclude subjects with diagnosed 
hypertension. However, the adjustments of SBP and DBP according to diagnostic 
hypertension avoided the possibility that a biased selection might result from selecting only 
individuals without hypertension. This correction has been widely adopted for different 
9 
 
authors [14-17]. Fifth, non-genetic factors could influence BP levels. In this sense, 
multivariate adjustments support that the effects are independent of some common traditional 
hypertension risk factors, including age, BMI, physical activity, smoking status and alcohol 
consumption. However, sodium intake was not taken into account, although it would be of 
interest to be included in the analysis, but unfortunately data were not available. Finally, as a 
cross-sectional study, to get definitive clinical conclusions about dietary intake may be 
elusive. 
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The present research represents a pilot effort to explore the role of gene-environment 
interactions in BP levels. The investigation of genetic factors and their interactions with the 
environment may improve the selection of more individualized effective treatment of 
hypertension. 
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Tables 
Table 1 Characteristics of the population by NOS3 rs1799983 genotype 
 Total 
mean (SD) 
GG  
mean (SD) 
GT 
mean (SD) 
TT 
mean (SD) p-value 
n (%) 705 283 (40.1) 324 (46.0) 98 (13.9) 0.733a
Women (%) 548 (77.7) 211 (29.9) 260 (36.9) 77 (10.9) - 
Age (years)b 50.2 (13.2) 50.6 (13.1) 50.7 (13.1) 47.7 (13.1) 0.121 
Anthropometric measurements 
Height (cm) b 163.0 (8.7) 163.0 (6.6) 163.0 (6.6) 163.2 (6.6) 0.886 
Weight (kg)c 78.3 (16.7) 77.9 (13.6) 79.3 (13.6) 75.9 (13.7) 0.083 
BMI c 29.5 (5.8) 29.3 (5.0) 29.8 (5.0) 28.7 (5.1) 0.155 
BFM (%)c 34.6 (10.2) 34.6 (7.4) 34.7 (7.4) 34.2 (7.4) 0.861 
Waist circumference (cm) c 96.5 (15.2) 95.8 (12.1) 97.4 (12.1) 95.2 (12.1) 0.157 
Physical activity c
Physical activity level c 1.23 (0.03) 1.23 (0.03) 1.23 (0.03) 1.24 (0.03) 0.153 
Baseline dietary intake 
Energy (kcal/day) d 2,149 (430) 2,138 (391) 2,150 (392) 2,144 (393) 0.791 
Carbohydrate (g/day) e 197.8 (71.4) 197.5 (53.3) 197.8 (53.3) 198.6 (53.4) 0.986 
Protein (g/day) e 92.9 (24.8) 93.2 (17.0) 92.7 (17.0) 92.8 (17.0) 0.962 
Fat (g/day) e 95.1 (22.4) 95.4 (16.6) 95.2 (16.7) 94.4 (16.7) 0.895 
    MUFA (g/day) e 46.6 (11.8) 46.9 (9.9) 46.5 (9.9) 45.9 (9.9) 0.641 
    PUFA (g/day) e 14.1 (3.7) 14.1 (2.6) 14.1 (2.6) 14.0 (2.6) 0.889 
    SFA (g/day) e 19.1 (5.4) 19.0 (4.0) 19.3 (4.0) 19.1 (4.0) 0.681 
455 
456 
457 
458 
459 
460 
461 
462 
463 
464 
465 
BMI, Body mass index; BFM, Body fat mass; %E, Percentage of energy; MUFA; Monounsaturated fatty acids; 
Polyunsaturated fatty acids; SFA, Saturated fatty acids 
a Hardy Weinberg Equilibrium 
b Adjusted for gender 
c Adjusted for gender, age and energy intake 
d Adjusted for gender, age and physical activity 
e Adjusted for gender, age, energy intake and physical activity 
 
Table 2 Association of the rs1799983 NOS3 genetic variant with Systolic and Diastolic BP 
among Southern Europeansa
 
  Model 1  Model 2 
 Genotype B (95% CI) p  B (95% CI) p 
SBP      
 Additive effect of T allele 1.06 (-0.95-3.07) 0.303  1.25 (-0.69-3.19) 0.205 
 GT vs GG 0.59 (-2.39-3.58) 0.696  -0.00 (-2.87-2.86) 0.998 
 TT vs GG 2.43 (-1.87-6.73) 0.267  3.38 (-0.76-7.53) 0.110 
 GT + TT vs GG  1.02 (-1.80-3.84) 0.478  0.78 (-1.93-3.49) 0.573 
 TT vs GG + GT 2.11 (-1.88-6.11) 0.299  3.38 (-0.47-7.24) 0.085 
DBP      
 Additive effect of T allele 1.81 (0.31-3.32) 0.018  1.99 (0.61-3.36) 0.005 
 GT vs GG 2.87 (0.63-5.10) 0.012  2.16 (0.13-4.20) 0.037 
 TT vs GG 2.90 (-0.32-6.12) 0.077  3.86 (0.91-6.80) 0.010 
 GT + TT vs GG  2.88 (0.77-5.00) 0.008  2.55 (0.63-4.47) 0.009 
 TT vs GG + GT 1.37 (-1.63-4.38) 0.370  2.71 (-0.04-5.45) 0.053 
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467 
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SBP, Systolic blood pressure; DBP, Diastolic blood pressure; 95% CI, 95% confidence interval 
a SBP + 15mmHg and DBP + 10mmHg to treated hypertensive subjects 
Model 1 adjusted for gender and age 
Model 2 adjusted for gender, age, BMI, physical activity, smoking status and alcohol consumption 
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Figures 
Figure 1. Risk of hypertension according to rs1799983 genotype 
Adjusted for gender, age, physical activity, energy intake, smoking status and alcohol consumption 
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Figure 2. Interaction between NOS3 and SFA (a) and MUFA (b) on DBP 
DBP, Diastolic blood pressure; SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids 
Adjusted for gender, age, physical activity, energy intake, smoking status and alcohol consumption 
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(b) 
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Figure 3. Interaction between NOS3 and obesity status on DBP 
Adjusted for gender, age, physical activity, energy intake, smoking status and alcohol consumption 
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